Actively Recruiting
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Led by AbbVie · Updated on 2026-04-07
120
Participants Needed
10
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled at 15 sites across Belgium. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
CONDITIONS
Official Title
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with advanced Parkinson's Disease
- Aged 18 years or older
- Able to provide voluntary informed consent
- Evaluated for continuous subcutaneous Foslevodopa/Foscarbidopa at hospital as part of routine care
- Intention to start subcutaneous Foslevodopa/Foscarbidopa treatment made prior to study recruitment
You will not qualify if you...
- Currently participating in an interventional research study (excluding noninterventional studies) during treatment
- Evaluated for continuous subcutaneous Foslevodopa/Foscarbidopa treatment outside of hospital
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Universitair Ziekenhuis Antwerpen /ID# 279434
Edegem, Antwerpen, Belgium, 2650
Actively Recruiting
2
Chu Tivoli /ID# 279455
La Louvière, Hainaut, Belgium, 7100
Actively Recruiting
3
Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452
Tournai, Hainaut, Belgium, 7500
Actively Recruiting
4
Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454
Hasselt, Limburg, Belgium, 3500
Actively Recruiting
5
UZ Gent /ID# 279433
Ghent, Oost-Vlaanderen, Belgium, 9000
Actively Recruiting
6
Universitair Ziekenhuis Leuven /ID# 279439
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
7
AZ Sint-Jan Brugge /ID# 279422
Bruges, West-Vlaanderen, Belgium, 8000
Actively Recruiting
8
Az Groeninge Campus Kennedylaan /ID# 279423
Kortrijk, West-Vlaanderen, Belgium, 8500
Actively Recruiting
9
AZ Oostende /ID# 279461
Ostend, West-Vlaanderen, Belgium, 8400
Actively Recruiting
10
AZ-Delta. /ID# 279437
Roeselare, West-Vlaanderen, Belgium, 8800
Actively Recruiting
Research Team
C
Clementine Semanaz
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here